MedTrace Logo

Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain

NCT06415175 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 143

Last updated 2026-02-25

No results posted yet for this study

Summary

This is a multicentre, prospective, non-interventional study that aims to describe the treatment patterns of in Atopic dermatitis (AD) patients aged 6 months to 11 years old in Spain: patients' characteristics, disease characteristics, prior treatments for and treatment prescription modalities. As well as to document the real-world effectiveness and safety of dupilumab during the two years of follow up. No diagnostic or therapeutic intervention outside of routine clinical practice will be applied.

Conditions

Interventions

DRUG

Dupilumab

This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Clinical Sciences & Operations · Sanofi

Eligibility

Min Age
6 Months
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-14
Primary Completion
2026-09-30
Completion
2027-11-23

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06415175 on ClinicalTrials.gov